Top Deals of 2024: Flo Health Secures $200M in Funding to Achieve Unicorn Status

This blog highlights one of the largest growth capital investments made in Femtech this year. Led by General Atlantic, the deal highlights a growing interest in the women’s health sector from prominent generalist firms.

Flo Health, the world’s most downloaded women’s health app, has announced it secured over $200 million in Series C funding from General Atlantic, a prominent global growth investor. This landmark investment propels Flo’s valuation beyond $1 billion, making it the first purely digital consumer women’s health app to achieve unicorn status.

Founded in 2015, Flo Health has become a pioneer in empowering women to take control of their health. Initially launched as a period tracker, the app has since evolved into a comprehensive platform that offers ovulation tracking, cycle predictions, and expert health insights. With over 50 million monthly active users globally, Flo has transformed into an indispensable tool for millions of women seeking personalized, data-driven health information.

Obtaining such a vast and personal data set has not come without scrutiny. In 2021, Flo Health reached a settlement with the Federal Trade Commission after it was found to have shared sensitive user data with third parties, including Facebook and Google, without proper disclosure. As part of the settlement, Flo agreed to obtain user consent before sharing health data, undergo independent privacy reviews, and notify affected users about past disclosures. This serves as a reminder of the importance of transparency and accountability as health tech continues to scale to meet women’s health needs.

Cycle tracking apps are increasingly integral in fertility planning, managing menopause symptoms, and offering personalized health recommendations based on individual patterns. By tracking menstrual cycles, users gain a deeper understanding of their hormonal fluctuations, which can help identify potential health issues at earlier stages. This valuable data is especially important for women managing conditions like polycystic ovary syndrome (PCOS), endometriosis, and fertility concerns. Additionally, it offers users a holistic way to monitor their overall well-being.

By safely giving women access to personalized insights, these apps foster empowerment and self-awareness, ensuring that women are better equipped to make informed decisions about their healthcare.


While Flo Health is a major player in this fast-evolving sector, it is by no means the only one driving change. There are several companies making strides in the women’s health space, each addressing unique needs. These players include:

Clue, Series C- An app for tracking menstrual cycles. The app is popular for its accurate predictions, based on a wide range of biological markers, and has been instrumental in research on reproductive health.

Rita Health, Seed - A reproductive health app focused on providing proactive, comprehensive fertility assessments and tracking, helping women assess their fertility potential and guiding them through their reproductive journeys.

Stardust App, Seed - An app that blends science and astronomy to track periods, hormones, ovulation, and pregnancy.

The surge in funding and the growing recognition of the value of women’s health innovation signals a transformative shift in the sector. As investment continues to flow into this space, we are witnessing the development of a more inclusive healthcare ecosystem. This shift promises to provide women with greater autonomy and personalized care, which is crucial as the industry pushes forward. With 2024 shaping up to be a pivotal year, the future of women’s health innovation looks brighter than ever.

Continue Reading

Top 10 Deals of 2024: Hologic Acquires Endomag for $310M

This week we highlight a second acquisition by the active women’s health acquirer, Hologic, in a large market segment of women’s health: breast cancer.

Top 10 Deals of 2024: IVI RMA Acquires Eugin Group for $535M

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

Top 10 Deals of 2024: Hologic Acquires Uterine Fibroid Treatment Company for $350M

This blog assesses a recent women’s health deal that expands treatment options for uterine fibroids and abnormal uterine bleeding. These indications are infrequently discussed and therefore unfamiliar to many, yet impact a significant number of women, especially those in perimenopause.

Top 10 Deals of 2024: Hologic Acquires Endomag for $310M

This week we highlight a second acquisition by the active women’s health acquirer, Hologic, in a large market segment of women’s health: breast cancer.

Top 10 Deals of 2024: IVI RMA Acquires Eugin Group for $535M

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

Fast track our industry.
Get in touch today.